Premium
Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy
Author(s) -
JENSEN JYTTE,
NILAS LISBETH,
CHRISTIANSEN CLAUS
Publication year - 1986
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1986.tb08035.x
Subject(s) - progestogen , norethisterone acetate , medicine , norethisterone , endocrinology , cholesterol , lipoprotein , adverse effect , high density lipoprotein , low density lipoprotein , hormone , chemistry , research methodology , population , environmental health
Summary. Cyclic changes in lipoproteins after sequential oestrogen‐progestogen therapy were studied in a group of healthy postmenopausal women treated with three different hormone doses, and followed up for two consecutive cycles by twice weekly examinations (a total of 17 examinations). There was a significant rise in high density lipoprotein (HDL) cholesterol and a significant fall in low density lipoprotein (LDL) cholesterol closely related to the dose of the oestrogen component. Addition of the progestogen, 1 mg of norethisterone acetate, decreased the oestrogen‐induced rise in HDL, but HDL levels remained higher than initial values in the high‐dose (4 mg) and medium dose (2 mg) groups. The average increases in HDL cholesterol were 13%, 9% and 2% in the high‐dose, medium‐dose and low‐dose (1 mg) groups, respectively, and the corresponding mean decreases in LDL cholesterol were 18%, 15% and 10% respectively. We conclude that postmenopausal treatment with sequentially combined oestrogen‐progestogen has no adverse effects on the lipoprotein status.